三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

已收盘 06-03 16:08:12

16.360

-0.510

-3.02%

最高16.910	最低16.130	成交量4,912万
今开16.900	昨收16.870	日振幅4.62%
总市值415.22亿	流通市值415.22亿	总股本25.38亿
成交额8.02亿	换手率1.94%	流通股本25.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":16.36,"timestamp":1780474092003,"preClose":16.87,"halted":0,"volume":49117171,"delay":0,"changeRate":-0.03023117960877306,"floatShares":2538000000,"shares":2538000000,"eps":3.967456269592477,"marketStatus":"已收盘","change":-0.51,"latestTime":"06-03 16:08:12","open":16.9,"high":16.91,"low":16.13,"amount":801643016,"amplitude":0.046236,"askPrice":16.37,"askSize":69500,"bidPrice":16.36,"bidSize":12000,"shortable":3,"etf":0,"ttmEps":3.967456269592477,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780536600000},"marketStatusCode":5,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":16.87,"dividendRate":0.015281,"openAndCloseTimeList":[[1780450200000,1780459200000],[1780462800000,1780473600000]],"volumeRatio":0.984376,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"1126429074","title":"三生制药授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1126429074","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126429074?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:40","pubTimestamp":1780476008,"startTime":"0","endTime":"0","summary":"三生制药于最新公告中披露，即将于2026年6月25日召开股东周年大会，就授予董事最高可购回不超过已发行股本10%的股份授权进行表决。董事会认为，这项购回授权有助于在市况适宜时提升公司价值及股东回报。董事会并强调，仅会在符合公司及股东整体利益的情况下行使相关权力，不会对公司正常营运及财务状况造成重大影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640597503","title":"医美概念承压 巨子生物(02367)领跌4.08% 机构指敷料药店渠道红利消退、行业进入存量竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2640597503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640597503?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:39","pubTimestamp":1780465177,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念普跌，截至发稿，巨子生物(02367)跌4.08%，医思健康(02138)跌3.66%，复星医药(02196)跌3.16%，康哲药业(00867)跌2.53%，四环医药(00460)跌2.08%，三生制药(01530)跌2.07%。消息面上，华龙证券新近研究指，当前医美行业政策端医保支付监管收紧，医美敷料药店渠道红利消退，行业合规化监管持续深化；医美行业进入存量竞争，循证诊疗、合规经营、精细化运营成为机构发展核心方向。产业端AI智能设备、数字化服务加速在美业线下场景渗透，数智化转型成为行业新趋势，区域美业展会加速全产业链资源整合与模式创新。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","BK1583","BK1191","BK1593","02196","IE00BMCWC346.EUR","01530","00867","BK1161","BK1207","SG9999015952.SGD","00460","IE00BGHQDM52.EUR","BK1600","02367","SG9999004220.SGD","IE00BYV24P56.USD","SG9999004311.SGD","LU2488822045.USD","SG9999015945.SGD","02138","HK0000165453.HKD","SG9999015978.USD","IE00BVYPNP33.GBP","BK1511","SG9999015986.USD","BK1215","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183510593","title":"异动解读 | ASCO催化后板块获利回吐，三生制药盘中大跌7.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183510593","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183510593?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:44","pubTimestamp":1780364661,"startTime":"0","endTime":"0","summary":"三生制药今日盘中股价出现大跌，跌幅达7.40%，引发市场关注。消息面上，此次下跌主要与生物科技板块整体回调有关。此前，在美国临床肿瘤学会（ASCO）年会期间，三生制药的核心管线SSGJ-707公布了亮眼的II期临床数据，推动其股价在近期连续大涨。随着ASCO相关利好的集中释放，整个生物科技板块在今日出现获利回吐压力，科伦博泰生物、康方生物、荣昌生物等多只个股均显著下跌，三生制药亦随之承压。此次板块性的回调，反映了市场在短期利好兑现后的正常调整行为。三生制药在经历前期上涨后，股价随板块波动属于市场常见现象。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189619589","title":"异动解读｜三生制药盘中下跌5.62%，ASCO催化后生物科技板块集体回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1189619589","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189619589?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:41","pubTimestamp":1780364494,"startTime":"0","endTime":"0","summary":"6月2日，三生制药盘中下跌5.62%，报17.26港元/股，成交额1.02亿港元。消息面上，此前ASCO年会期间，三生制药核心管线SSGJ-707两项II期临床数据亮眼，推动公司股价在5月29日及6月1日连续大涨，累计涨幅显著。今日生物科技板块整体大幅回调，科伦博泰生物跌7.44%、康方生物跌6.38%、荣昌生物跌4.15%、信达生物跌3.65%、百济神州跌2.97%，板块在前期ASCO催化集中释放后出现获利回吐压力，三生制药亦随之承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105003877","title":"三生制药更新5月股份变动月报表，股本微增45,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1105003877","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105003877?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:55","pubTimestamp":1780304110,"startTime":"0","endTime":"0","summary":"三生制药于2026年6月1日披露了截至2026年5月31日的证券变动月报表。公告显示，公司法定股本及已发行股份结构在报告期内出现小幅变动。根据公告信息，截至5月末，公司法定股本依旧为50,000,000,000股，面值每股0.00001美元，对应法定/注册股本总额500,000美元，与上月底持平。本月普通股的已发行股份数量由原先的2,538,039,412股增至2,538,084,412股，新增45,000股，主要源自员工股份期权行使。截至2026年5月31日，三生制药已发行股份总数为2,538,084,412股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183905644","title":"异动解读 | ASCO年会临床数据亮眼叠加板块走强，三生制药盘中大涨6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183905644","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183905644?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:37","pubTimestamp":1780277839,"startTime":"0","endTime":"0","summary":"三生制药今日盘中大涨6%，引起了市场的广泛关注。消息面上，在ASCO年会期间，三生制药核心管线PD-1/VEGF双特异性抗体SSGJ-707的两项临床研究入选大会，其中一项更获得了快速口头报告资格。根据已公布的摘要，SSGJ-707单药治疗晚期非小细胞肺癌的II期研究确认客观缓解率高达67.6%，中位无进展生存期为12.4个月；其联合化疗一线治疗子宫内膜癌的确认客观缓解率也分别达到85.7%和80.0%，数据表现十分亮眼，增强了市场对公司研发前景的信心。与此同时，今日生物科技板块整体表现偏强，形成板块共振，进一步提振了市场情绪，共同推动了公司股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138329366","title":"异动解读｜三生制药盘中上涨8%，ASCO年会SSGJ-707临床数据持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1138329366","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138329366?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:30","pubTimestamp":1780277449,"startTime":"0","endTime":"0","summary":"6月1日，三生制药盘中上涨8%，报19.91港元/股，成交额5209.95万港元。消息面上，ASCO年会期间三生制药核心管线PD-1/VEGF双特异性抗体SSGJ-707两项临床研究入选大会，其中一项获快速口头报告资格。据已公布摘要，SSGJ-707单药治疗晚期NSCLC的II期研究确认ORR达67.6%，中位PFS为12.4个月；联合化疗一线治疗子宫内膜癌确认ORR分别为85.7%和80.0%，数据表现亮眼。同期生物科技板块整体偏强，康方生物涨11.94%、科伦博泰生物涨6.10%，板块共振进一步提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195630704","title":"异动解读｜三生制药开盘上涨5.95%，ASCO年会SSGJ-707临床数据持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1195630704","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195630704?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:20","pubTimestamp":1780276854,"startTime":"0","endTime":"0","summary":"6月1日，三生制药开盘上涨5.95%，报19.6港元/股，成交额963.85万港元。消息面上，ASCO年会期间三生制药核心管线PD-1/VEGF双特异性抗体SSGJ-707两项临床研究入选大会，其中一项获快速口头报告资格。据已公布摘要，SSGJ-707单药治疗晚期NSCLC的II期研究确认ORR达67.6%，中位PFS为12.4个月；联合化疗一线治疗子宫内膜癌确认ORR分别为85.7%和80.0%，数据表现亮眼。同期生物科技板块整体偏强，科伦博泰生物涨5.37%、百济神州涨1.3%，板块共振进一步提振市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152411285","title":"异动解读 | ASCO年会数据亮眼，三生制药盘中大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152411285","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152411285?lang=zh_cn&edition=full","pubTime":"2026-05-29 12:01","pubTimestamp":1780027312,"startTime":"0","endTime":"0","summary":"三生制药今日盘中大涨5.10%，引起了市场的广泛关注。消息面上，美国临床肿瘤学会年会于今日正式开幕，三生制药的核心在研管线PD-1/VEGF双特异性抗体SSGJ-707的两项临床研究入选大会，其中一项获得了快速口头报告资格。与此同时，今日生物科技板块整体表现强势，板块内的共振效应也为三生制药的股价上涨提供了额外的助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196087472","title":"异动解读｜三生制药盘中上涨5.1%，ASCO年会开幕SSGJ-707数据集中亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=1196087472","media":"行情直击","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196087472?lang=zh_cn&edition=full","pubTime":"2026-05-29 11:50","pubTimestamp":1780026604,"startTime":"0","endTime":"0","summary":"5月29日，三生制药盘中上涨5.1%，报18.13港元/股，成交额2.48亿港元。消息面上，ASCO年会于今日正式开幕，三生制药核心管线PD-1/VEGF双特异性抗体SSGJ-707两项临床研究入选本届大会，其中一项获快速口头报告。据已公布摘要，SSGJ-707单药治疗晚期NSCLC的II期研究显示确认ORR达67.6%，中位PFS为12.4个月；联合化疗一线治疗子宫内膜癌的II期研究中，确认ORR分别为85.7%和80.0%。同日生物科技板块整体走强，信达生物涨10.35%，康方生物涨7.07%，板块共振进一步提振市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638251755","title":"三生制药(01530)拟委任毕马威为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2638251755","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638251755?lang=zh_cn&edition=full","pubTime":"2026-05-26 21:01","pubTimestamp":1779800519,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药 发布公告，经考虑安永会计师事务所(安永)已担任本公司核数师逾15年，聘请具备同等资质的新核数师于未来数年为本公司及其附属公司进行审计工作将更加符合良好企业惯例。安永将于2026年股东周年大会结束时任期届满而煺任本公司核数师，且不会获续聘。鉴于毕马威上述品质，根据审计委员会的推荐，董事会认为建议委任毕马威为本公司核数师符合本公司及股东的整体利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1593","HK0000165453.HKD","01530"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636093489","title":"中泰证券：三生制药市值天花板已打开 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2636093489","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636093489?lang=zh_cn&edition=full","pubTime":"2026-05-17 11:10","pubTimestamp":1778987400,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　中泰证券发布研报称，预计三生制药（01530）2026~2028年实现营业收入97.06/113.26/128.70亿元，前值2026-2027收入114.94/131.53亿元，实现归母净利润22.68/31.58/36.66亿元，前值2026-2027归母净利润26.48/30.27亿元，小幅调整主要系根据2025年国内药品商业化情况外推。公司707海外合作稳固，市值天花板已打开。维持“买入”评级。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-17/doc-inhyekzt3786836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600918","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706802","title":"中泰证券：维持三生制药(01530)“买入”评级 早研管线蕴含多个中美双报FIC","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706802","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706802?lang=zh_cn&edition=full","pubTime":"2026-05-15 14:47","pubTimestamp":1778827630,"startTime":"0","endTime":"0","summary":"维持“买入”评级。国际学术会议持续亮相，包括在2026 AACR复现了国内的临床前和早期数据，其对VEGF的结合亲和力高于bevacizumab或VEGF/PD-1竞品；将在ASCO分享单药1LPD-L1+NSCLCII期数据、联用化疗用于1L晚期复发子宫内膜癌的数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600918","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634102264","title":"中邮证券：维持三生制药(01530)“买入”评级 多项临床开展全球价值加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2634102264","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634102264?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:46","pubTimestamp":1778564812,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中邮证券发布研报称，三生制药系国内医药领域的老牌企业，坐拥特比澳等多个现金牛品种，为研发创新输入动力。对外授权落地推动业绩高增，主业受政策扰动有所下滑公司与辉瑞就PD-1/VEGF双抗707达成的授权交易在报告期内确认了94.3亿元的许可收入，构成了总收入的53.3%。707授权辉瑞，多项临床开展全球价值加速兑现PD-1/VEGF双抗被视为下一代肿瘤免疫治疗的核心基石疗法，市场空间广阔。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633486142","title":"医美概念股普跌 三生制药(01530)领跌2.88% 机构指美容护理板块现处于“三低”状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2633486142","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633486142?lang=zh_cn&edition=full","pubTime":"2026-05-08 13:24","pubTimestamp":1778217872,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股普跌，截至发稿，三生制药(01530)跌2.88%，卓珈控股(01827)跌2.22%，康哲药业(00867)跌2.06%，复锐医疗科技(01696)跌2.02%，四环医药(00460)跌1.61%。消息面上，华泰证券表示，美容护理板块现处于预期低/估值低/持仓低的“三低”状态，行业面/资金面/基本面等维度的边际改善均有可能带来积极变化。从财报情况来看，部分标的业绩改善迹象已现，复苏节奏和斜率略有差异。整体而言品牌商及医美上游厂商分化明显，代工厂逐步复苏，代运营商转型持续兑现。建议积极跟踪618/新品势能等催化剂，若个股有盈利预测上修潜力，戴维斯双击或可期待。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980934","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNP33.GBP","BK1583","01696","BK1161","BK1585","BK1515","LU2488822045.USD","IE00BVYPNQ40.USD","BK1600","BK1100","SG9999004220.SGD","HK0000165453.HKD","SG9999015986.USD","BK1593","BK1191","01827","00460","IE00BYV24P56.USD","SG9999015952.SGD","SG9999015945.SGD","SG9999015978.USD","BK1215","IE00BGHQDM52.EUR","00867","01530","IE00BMCWC346.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","BK1585","BK1588","02268","LU0417516902.SGD","01530","LU0348783233.USD","LU1794554557.SGD","BK1141","LU2476274720.SGD","01099","02367","02196","BK1197","LU0417516738.SGD","01789","LU0640798160.USD","LU0634319403.HKD","BK1583","HK0000165453.HKD","06821","LU0348735423.USD","BK1500","CXO","02228","601881","LU0588546209.SGD","LU1251922891.USD","BK0188","LU1961090484.USD","BK1207","LU2488822045.USD","BK1593","LU0348766576.USD","LU1719994722.HKD","LU2328871848.SGD","LU1303224171.USD","LU0307460666.USD","IE00BPRC5H50.USD","LU2778985437.USD","06160","09688","03933","BK0276","LU0417516571.SGD","LU0348767384.USD","BK1161","LU1969619763.USD","09926","06881"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174317146","title":"异动解读 | 三生制药盘中大涨5.71%，Summit暴跌余波消退叠加生物科技板块集体反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1174317146","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174317146?lang=zh_cn&edition=full","pubTime":"2026-05-07 10:35","pubTimestamp":1778121316,"startTime":"0","endTime":"0","summary":"三生制药今日盘中大涨5.71%，引起了市场的广泛关注。消息面上，此前其合作伙伴Summit Therapeutics因财报不佳而暴跌，导致市场对双方核心管线AK112的预期下修，三生制药股价因此连续承压。当前，由该事件引发的恐慌情绪已得到充分释放。与此同时，生物科技板块今日整体呈现回暖态势，多只相关个股上涨，三生制药也随板块一同出现修复性反弹。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190557799","title":"三生制药4月股份变动：小幅增发34,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1190557799","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190557799?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:36","pubTimestamp":1778056585,"startTime":"0","endTime":"0","summary":"三生制药于2026年5月6日向香港联交所提交截至2026年4月30日止的股份变动月报表。报告显示，公司于4月期间因行使购股权新增发行34,000股普通股，发行后已发行股本从上月的2,538,005,412股上升至2,538,039,412股。本月因购股权行使所取得资金为259,080港元。月报显示，公司确认符合香港联交所对最低公众持股量的相关规定。公司表示会继续严格遵守香港联交所《上市规则》及相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150552598","title":"异动解读 | 多重利好催化，三生制药盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150552598","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150552598?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:41","pubTimestamp":1777516861,"startTime":"0","endTime":"0","summary":"三生制药今日盘中大涨5.04%，引起了市场的广泛关注。消息面上，多家券商发布研报力挺三生制药，华源证券维持\"买入\"评级，方正证券维持\"强烈推荐\"评级。公司基本面表现亮眼，营业收入和净利润均实现大幅增长，主要受益于与辉瑞就PD-1/VEGF双抗SSGJ-707达成授权交易，并确认了高额许可收入。此外，国家药监局近日授予公司艾曲泊帕乙醇胺干混悬剂新增适应症批件，同时公司即将在ASCO大会上发布SSGJ-707的两项核心临床数据，研发管线推进预期持续升温。南向资金近期亦持续加仓，且公司当前静态市盈率仅6.74倍，估值处于历史低位，共同构成了股价上涨的催化剂。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631577846","title":"港股异动 | 三生制药(01530)现涨超5% SSS68注射液三项适应症获中国IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631577846","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631577846?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:34","pubTimestamp":1777516454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药现涨超5%，截至发稿，涨5.13%，报23.36港元，成交额3.02亿港元。值得一提的是，SSS68注射液是全球首个进入临床阶段的APRIL×BAFF双抗。值得注意的是，4月28日，三生制药自主研发的1类治疗用生物制品SSGJ-706注射液新药临床试验申请正式获得受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK4588","BK1583","HK0000165453.HKD","IND","BK1161","VXUS","BK4585","01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.0761},{"period":"1month","weight":-0.271},{"period":"3month","weight":-0.1419},{"period":"6month","weight":-0.4324},{"period":"1year","weight":-0.1031},{"period":"ytd","weight":-0.3023}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0312},{"period":"6month","weight":0.0039},{"period":"1year","weight":0.1244},{"period":"ytd","weight":0.0159}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.00666},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00178},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113214},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080954},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025246},{"month":7,"riseRate":0.090909,"avgChangeRate":-0.038254},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.014022},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027455},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018307},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059913},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045323}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}